Allarity Therapeutics to Present at Biomarkers 2024

Core Insights - Allarity Therapeutics, Inc. has been invited to present at Biomarkers 2024, showcasing its advancements in personalized cancer treatments [1][2] Group 1: Company Overview - Allarity Therapeutics is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly stenoparib, a dual PARP/Tankyrase inhibitor for advanced ovarian cancer [5] - The company utilizes its Drug Response Predictor (DRP®) companion diagnostic platform to select patients likely to benefit from specific treatments, enhancing therapeutic benefit rates [4][5] Group 2: Presentation Details - Thomas Jensen, CEO and co-founder, will present on a gene expression-based biomarker for predicting treatment response at Biomarkers 2024 on February 29, 2024, in London, UK [3] - The presentation will cover the development of the DRP® platform, which has shown statistically significant predictions of clinical outcomes in 37 out of 47 clinical studies [4] Group 3: Clinical Trials - An ongoing phase 2 clinical trial (NCT03878849) is investigating the efficacy of stenoparib in advanced ovarian cancer patients, utilizing the DRP® for patient selection [2][5] - The trial is being conducted at multiple sites across the US and Europe, emphasizing the company's commitment to addressing unmet medical needs in cancer treatment [2][5]